Ribonucleotide Reductase Inhibitors Pipeline Market Research Report 2021 Featuring Astex Pharmaceuticals, Trethera, Vion Pharmaceuticals, & Treovir – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ribonucleotide Reductase Inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Ribonucleotide reductase inhibitors – Pipeline Insight, 2021” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Ribonucleotide reductase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ribonucleotide reductase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Ribonucleotide reductase inhibitors.

Ribonucleotide reductase inhibitors Emerging Drugs Chapters

This segment of the Ribonucleotide reductase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ribonucleotide reductase inhibitors Emerging Drugs

G207: Treovir, LLC

G207 is engineered so that it selectively infects and kills tumor cells leaving healthy cells unharmed. Death of infected tumor cells releases G207 that spreads to infect additional tumor cells and to elicit a florid T-cell immune-related inflammatory response within the tumor. It is believed that the patient’s own immune response is a major basis for the anti-tumor efficacy of G207. G207 has been awarded Orphan Drug designation by the US FDA for treatment of medulloblastoma, Glioblastoma and primitive neuroectodermal brain tumor. The drug is currently being evaluated in Phase II stage of development for the treatment of pediatric high-grade glioma.

Ribonucleotide reductase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Ribonucleotide reductase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ribonucleotide reductase inhibitors

There are approx. 3+ key companies which are developing the therapies for Ribonucleotide reductase inhibitors. The companies which have their Ribonucleotide reductase inhibitors drug candidates in the most advanced stage, i.e. phase II include Treovir, LLC.

Key Questions Answered

• How many companies are developing Ribonucleotide reductase inhibitors drugs?
• How many Ribonucleotide reductase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ribonucleotide reductase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ribonucleotide reductase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ribonucleotide reductase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Topics Covered:

Introduction

Executive Summary

Ribonucleotide reductase inhibitors: Overview

• Structure
• Function

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Mid Stage Products

• Comparative Analysis

G207: Treovir, LLC

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products

• Comparative Analysis

TAS1553: Astex Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Ribonucleotide reductase inhibitors Key Companies

Ribonucleotide reductase inhibitors Key Products

Ribonucleotide reductase inhibitors- Unmet Needs

Ribonucleotide reductase inhibitors- Market Drivers and Barriers

Ribonucleotide reductase inhibitors- Future Perspectives and Conclusion

Ribonucleotide reductase inhibitors Analyst Views

Ribonucleotide reductase inhibitors Key Companies

Appendix

Companies Mentioned

• Astex Pharmaceuticals
• Trethera
• Vion Pharmaceuticals
• Treovir, LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8mmepo

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900